Cancer Radiotherapie肿瘤放射治疗
Cancer Radiotherapie(英文缩写 CANCER RADIOTHER),ISSN 1278-3218,eISSN 1769-6658,中文译名:肿瘤放射治疗 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-10-01 至 2026-09-30，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 1.217 | Q4 |
| 2022 | 1.300 | Q4 |
| 2023 | 1.500 | Q3 |
| 2024 | 1.400 | Q3 |
| 2025 | 1.300 | Q4 |
Cancer Radiotherapie 最新收录文献
-
1. Intracranial mesenchymal tumours with FET::CREB fusions: Two case reports and literature review.
PMID:日期:2026-09-23Intracranial mesenchymal tumours with in-frame gene fusions of the FET family of RNA-binding proteins to the cyclic AMP response element-binding protein family of transcription factors are exceptionally rare primary central nervous system neoplasms, with morphological similarities to angiomatoid fibrous histiocytoma. Despite their recent inclusion in the 2021 World Health Organisation classification of tumours of the central nervous system, only a limited number of cases have been reported. We describe two cases of intracranial mesenchymal tumours harbouring fusion of the Ewing sarcoma breakpoint region 1 gene with the activating transcription factor 1 gene, both arising from the falx cerebri. Clinical, radiological, pathological, molecular, and therapeutic findings are detailed. A literature review was performed to contextualize our observations. Case 1 involved a 32-year-old man with a parafalcine lesion initially mimicking meningioma, treated with subtotal resection followed by adjuvant radiotherapy. Case 2 concerned a 69-year-old woman with a similar lesion, managed with gross total resection and radiotherapy. Histopathology in both cases revealed epithelioid morphology within myxoid or fibrous stroma, with desmin, epithelial membrane antigen, and CD99 positivity. Molecular analyses confirmed fusion of the Ewing sarcoma breakpoint region 1 gene with the activating transcription factor 1 gene. After 38 and 30 months of follow-up, respectively, both patients remained recurrence-free. These cases reinforce the recognition of intracranial mesenchymal tumours with gene fusions of the FET family of RNA-binding proteins to the cyclic AMP response element-binding protein family of transcription factors as a distinct entity. Accurate diagnosis requires combined histopathological and molecular evaluation. While gross total resection remains the preferred approach, adjuvant radiotherapy may improve disease control. Larger multicentre studies are needed to refine prognostic factors and therapeutic recommendations.
-
2. Management of cervical cancer with lymph nodes involvement in a large tertiary centre: Results from the preimmunotherapy era.
PMID:日期:2026-09-23This study aimed to assess the specific outcomes of patients locally advanced node-positive cervical cancer according to the International Federation of Gynaecology and Obstetrics receiving concurrent chemoradiotherapy and image-guided adaptive brachytherapy before adjuvant immunotherapy. A cohort of 388 women with non-metastatic advanced cervical cancer and lymph node involvement treated at a single tertiary centre (2016-2021) was analysed. All patients underwent chemoradiotherapy followed by brachytherapy. Disease-free survival and overall survival were compared between patients with only pelvic node involvement (n=175) and those with at least para-aortic node involvement (n=213), as well as across node staging methods. Notably, some patients also had bladder or rectal involvement. With a median follow-up of 54.8 months, 152 progressions or recurrences were reported, including metastatic event in 99 cases (65.1 % of first events). Additionally, 22 deaths occurred without previous progression/relapse. This resulted in a 5-year disease-free survival rate of 50.8 % (95 % confidence interval [CI]: 45.2-56.2 %) for the entire cohort, significantly differing between the pelvic (58.5 %; 95 % CI: 50.1-65.9 %) and para-aortic (44.2 %; 95 % CI: 36.7-51.4 %) groups (p=0.007). The 5-year overall survival rate was 61.0 % (95 % CI: 55.7-65.8 %) in the entire cohort and was poorer in patients with para-aortic involvement (52.5 %; 95 % CI: 45.1-59.3 %; p=0.002). A larger high-risk clinical target volume at least 43.5cm (p=0.0001), para-aortic node involvement (p=0.01), and a total treatment duration of more than 55 days (p=0.01) were associated with a higher recurrence risk. Chemoradiotherapy followed by brachytherapy is effective and feasible for patients with node-positive cervical cancer. However, two-thirds of progressions or recurrences involved a distant event, suggesting the need to evaluate incremental systemic treatment strategies.
-
4. Survival outcomes of trimodal treatment for stage IVB endometrial cancer: A retrospective single-centre cohort study.
PMID:日期:2026-09-23The purpose of this study was to evaluate survival outcomes of multimodal treatment, including chemotherapy, surgery, and radiotherapy, of patients with stage IVB endometrial carcinoma treated at a single institution. We retrospectively identified 56 patients with stage IVB according to the International Federation of Gynaecology and Obstetrics endometrial carcinoma treated between 2004 and 2017. All patients received chemotherapy. Survival outcomes were analysed in the overall cohort and according to treatment strategies. With a median follow-up of 7.5 years, overall survival rates at 2, 3, and 5 years were 57.1 %, 46.4 %, and 32.1 %, respectively. Progression-free survival rates at 2, 3, and 5 years were 35.7 %, 28.6 %, and 23.2 %, respectively. Patients with a single metastatic site had significantly better outcomes compared with those with multiple metastatic sites. Among patients undergoing trimodal therapy, survival outcomes were more favourable, particularly in those with limited metastatic burden. Multimodal treatment including surgery and radiotherapy was associated with improved survival outcomes in selected patients with stage IVB endometrial cancer. These findings support a personalized treatment strategy based on metastatic burden and response to systemic therapy.
-
5. Modern adjuvant radiotherapy for breast adenoid cystic carcinoma: Clinical outcomes across normofractionated and hypofractionated schedules.
PMID:日期:2026-09-23Breast adenoid cystic carcinoma is a rare triple-negative breast cancer subtype with a favourable prognosis. While hypofractionated and ultra-hypofractionated radiotherapy are increasingly used for breast cancer, no dedicated data exist for breast adenoid cystic carcinoma. This study reports contemporary oncological outcomes, radiotherapy parameters, and toxicity in a uniformly treated single-institution cohort. We retrospectively reviewed files of all patients with non-metastatic breast adenoid cystic carcinoma treated with surgery and adjuvant radiation between 2006 and 2023. Clinical, pathological, treatment, and follow-up data were analysed. Survival was estimated using Kaplan-Meier methods. The data from 13 women (median age 69 years, range 47-79 years) were included; 92.3 % underwent breast-conserving surgery, and all were node-negative. Hypofractionation was used in 69.2 %, including three ultra-hypofractionated regimens (32.5 Gy delivered in five fractions). At a median follow-up of 60 months, there were no regional or distant recurrences and one local recurrence salvaged surgically. Five- and 10-year cancer-specific survival rates were 100 %, overall survival rates were 90.0 % and 67.5 %, respectively, and local recurrence-free survival rate was 90.0 % at both time points. Eight patients developed grade 1 acute radiodermatitis; no other acute or late toxicity events were observed. Modern adjuvant radiotherapy for breast adenoid cystic carcinoma provides excellent long-term local control with minimal toxicity. Hypofractionated and ultra-hypofractionated schedules appear safe and efficient. Prospective collaborative studies are needed to define the role of boost and optimal fractionation strategies in this rare histology.
-
6. Spatially fractionated radiotherapy as an alternative to brachytherapy for cervical cancer with unfavourable dosimetry: An in-silico study.
PMID:日期:2026-09-23Brachytherapy is a critical component of cervical cancer treatment, but unfavourable anatomy or poor tumour response to external beam radiotherapy can make brachytherapy technically difficult or suboptimal, resulting in inadequate target coverage or unacceptable organ-at-risk doses. This study evaluated the dosimetric feasibility of spatially fractionated radiotherapy as an alternative boost option when brachytherapy cannot be optimally delivered. An in-silico study was performed using volumetric-modulated arc therapy-based spatially fractionated radiotherapy on imaging data from ten patients who received brachytherapy between 2018 and 2021. These patients had suboptimal brachytherapy dosimetry due to unfavourable anatomy and/or large residual disease, or required advanced intracavitary-interstitial techniques. Before brachytherapy, magnetic resonance imaging was used to delineate the high-risk clinical target volume, and organs-at-risk were contoured on contrast-enhanced computed tomography. Two spatially fractionated radiotherapy plans were developed: (i) using straight virtual "rods" and (ii) using bending "rods". These virtual rods represented intentionally placed high-dose regions to recreate the heterogenous dose distribution characteristic of brachytherapy. Spatially fractionated radiotherapy plans were compared with clinically delivered brachytherapy plans. Both spatially fractionated radiotherapy approaches achieved high-risk clinical target D90 matching or exceeding brachytherapy across all patients. In cases with large residual tumours or unfavourable anatomy (n=7), spatially fractionated radiotherapy produced higher target coverage than brachytherapy. In patients with favourable intracavitary-interstitial brachytherapy dosimetry (n=3), spatially fractionated radiotherapy achieved comparable target doses. Bladder and rectum doses exceeded recommended constraints in seven of ten brachytherapy plans, whereas all spatially fractionated radiotherapy plans maintained organ-at-risk doses within recommended hard constraints. Spatially fractionated radiotherapy may offer a feasible alternative boost strategy for patients in whom brachytherapy is technically limited or yields suboptimal dosimetry. While not intended to replace brachytherapy, it may help bridge treatment gaps in challenging clinical scenarios.
-
7. General technical considerations on reirradiation and focus on brain and head and neck tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique.
PMID:日期:2026-09-23The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making relies on a delicate balance between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomized data, there is an increasing number of data encouraging its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from supranational scientific societies, the following publication is based on the "Recommendations Commission" of the Société française de radiothérapie oncologique (the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on brain tumours and head and neck cancers.
-
10. Hypofractionated radiotherapy for localized prostate cancer: From phase III evidence to real-world outcomes with or without elective pelvic nodal irradiation.
PMID:日期:2026-09-23Hypofractionated radiotherapy is a standard treatment for localized prostate cancer, supported by phase III trials showing non-inferiority versus conventional fractionation. However, most trials excluded elective pelvic lymph node irradiation, so evidence remains limited when pelvic nodes are treated. The primary objective of this study was to compare clinical outcomes and toxicity profiles between normofractionated radiotherapy and moderately hypofractionated radiotherapy. We performed a narrative review of phase III trials evaluating moderate or ultra-hypofractionated radiotherapy, then conducted a retrospective single-institution analysis comparing conventional fractionation (delivering 80Gy in 40 fractions) with moderate hypofractionation (delivering 72.5Gy in 29 fractions), with or without elective pelvic lymph node irradiation. The primary endpoint was disease-free survival. Secondary endpoints were overall survival and acute and late genitourinary and gastrointestinal toxicity. Eleven phase III trials were identified, confirming non-inferiority of moderate hypofractionation for prostate-only irradiation. In our cohort of 156 patients (76 treated with conventional fractionation and 80 with moderate hypofractionation), half received elective pelvic lymph node irradiation, and three quarters received androgen deprivation therapy. After a median follow-up of 69 months, 5-year disease-free survival was 85 % with conventional fractionation and 84 % with moderate hypofractionation, with similar five-year overall survival (88 % and 84 %). Grade 2 or higher acute genitourinary toxicity was more frequent with moderate hypofractionation, whereas late genitourinary and gastrointestinal toxicities were comparable. Moderate hypofractionation achieved disease control similar to conventional fractionation with acceptable toxicity, including in patients receiving elective pelvic lymph node irradiation. These findings support extension of moderate hypofractionation to patients requiring pelvic treatment and the need for prospective validation and integration with androgen deprivation therapy and stereotactic radiotherapy.